financetom
Business
financetom
/
Business
/
US health agency fires official who opposed mRNA Covid shots
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US health agency fires official who opposed mRNA Covid shots
Oct 28, 2025 10:48 AM

Oct 28 (Reuters) - A senior biosecurity adviser at the

Department of Health and Human Services, who has made several

critical statements regarding mRNA COVID-19 vaccines, was fired

over the weekend, an agency official told Reuters.

Steven Hatfill, who served as a senior adviser at the

agency's Administration for Strategic Preparedness and Response,

was fired on Saturday.

The agency cited false claims of being the chief medical

officer at ASPR and lack of effective cooperation with

government agencies and department leadership as reasons for the

ouster, according to Bloomberg News, which had reported the

development earlier in the day.

"He (Hatfill) was senior advisor, not chief medical advisor

or chief medical officer," the HHS official said, but did not

immediately clarify whether this was related to his dismissal.

Hatfill could not be immediately reached for comment.

ASPR leads the nation's medical and public health

preparedness for and response to disasters and public health

emergencies.

The Biomedical Advanced Research and Development Authority,

a research unit of ASPR which helps companies develop medical

supplies to address public health threats, had said in August it

would wind down mRNA vaccine development activities.

The decision included the cancellation of a contract

awarded to Moderna ( MRNA ) for the late-stage development of

its bird flu vaccine for humans.

Hatfill appeared on a show hosted by right-wing podcaster

Steve Bannon days after the BARDA announcement and claimed mRNA

vaccines caused "biochemical havoc" in cells.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Klaviyo Insider Sold Shares Worth $375,381, According to a Recent SEC Filing
Klaviyo Insider Sold Shares Worth $375,381, According to a Recent SEC Filing
Oct 10, 2025
05:42 PM EDT, 10/10/2025 (MT Newswires) -- Amanda Whalen, Chief Financial Officer, on October 10, 2025, sold 15,000 shares in Klaviyo ( KVYO ) for $375,381. Following the Form 4 filing with the SEC, Whalen has control over a total of 481,719 Series A common shares of the company, with 481,719 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1835830/000147083125000254/xslF345X05/wk-form4_1760132172.xml ...
Travel tech firm Navan eyes $6.45 billion valuation in US IPO
Travel tech firm Navan eyes $6.45 billion valuation in US IPO
Oct 10, 2025
Oct 10 (Reuters) - Corporate travel and expense company Navan said on Friday it is targeting a valuation of up to $6.45 billion in its U.S. initial public offering. The firm plans to raise $960 million by offering 36.92 million shares priced between $24 and $26 apiece. U.S. IPO activity has picked up in recent months following a lull caused...
US will impose additional 100% tariff on Chinese imports from November, Trump says
US will impose additional 100% tariff on Chinese imports from November, Trump says
Oct 10, 2025
(Reuters) -The United States of America will slap an additional 100% tariff on imports from China and impose export controls on all critical U.S.-made software from November 1, President Donald Trump said on Friday. In a post on Truth Social, Trump said: Starting November 1st, 2025 (or sooner, depending on any further actions or changes taken by China), the United...
Supernus Pharmaceuticals Insider Sold Shares Worth $3,029,336, According to a Recent SEC Filing
Supernus Pharmaceuticals Insider Sold Shares Worth $3,029,336, According to a Recent SEC Filing
Oct 10, 2025
05:36 PM EDT, 10/10/2025 (MT Newswires) -- Jack A. Khattar, Director, President, CEO, on October 09, 2025, sold 59,900 shares in Supernus Pharmaceuticals ( SUPN ) for $3,029,336. Following the Form 4 filing with the SEC, Khattar has control over a total of 2,212,178 common shares of the company, with 1,206,578 shares held directly and 1,005,600 controlled indirectly. SEC Filing:...
Copyright 2023-2026 - www.financetom.com All Rights Reserved